Status:

COMPLETED

The Effects of Bifidobacterium Breve Bif195 for Diarrhea-predominant Irritable Bowel Syndrome

Lead Sponsor:

Hvidovre University Hospital

Collaborating Sponsors:

Chr Hansen

Conditions:

Irritable Bowel Syndrome

Eligibility:

All Genders

18-60 years

Phase:

NA

Brief Summary

The purpose of this study is to investigate if the probiotic Bifidobacterium breve Bif195 (Bif195) will result in improvement in clinical outcome in patients with diarrhea-predominant irritable bowel ...

Detailed Description

IBS is the most frequently diagnosed gastrointestinal disease and also the most common cause of referrals to gastroenterology departments in Denmark. The possibilities for treatment for IBS are limit...

Eligibility Criteria

Inclusion

  • Diagnosed with IBS-D defined as more than one-fourth (25%) of bowel movements with Bristol Stool Scale Types 6-7 and less than one-fourth (25%) with Types 1-2
  • Fulfill Rome IV diagnostic criteria for IBS
  • Moderate to severe disease activity (IBS-SSS ≥175)
  • Able to read and speak Danish
  • Normal colonoscopy (performed within 1 year) if the patient had blood in stool

Exclusion

  • Other chronic gastro intestinal diseases including lactose intolerance and coeliac disease
  • Fecal calprotectin ≥50 mg/kg
  • Fecal sample positive for enteropathogenic microorganisms
  • Surgical interventions in the GI region (except for appendectomy, hernia repair, cholecystectomy and gynecological and urological procedures)
  • Psychiatric disorder
  • Abuse of alcohol or drugs
  • Medications except birth control pills, hormone supplements, allergies/asthma agents, blood pressure and cholesterol-lowering agents, proton pump inhibitors and non-prescription medicines; abnormal colonoscopy findings
  • Pregnancy, planned pregnancy or breastfeeding females
  • Ingestion of probiotics or antibiotics \<4 weeks before the inclusion
  • Abnormal screening biochemistry

Key Trial Info

Start Date :

April 16 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 9 2023

Estimated Enrollment :

61 Patients enrolled

Trial Details

Trial ID

NCT04808271

Start Date

April 16 2021

End Date

May 9 2023

Last Update

July 6 2023

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Hvidovre Hospital, Copenhagen University

Hvidovre, Copenhagen, Denmark, 2650

2

Copenhagen University Hospital Hvidovre

Hvidovre, Denmark, 2650